Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Serum Laboratory Studies, Stool Test, Breath Test01:30

Serum Laboratory Studies, Stool Test, Breath Test

Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early and late-onset colorectal cancers: a case-case comparison of risk factors.

Cancer causes & control : CCC·2026
Same author

Optimizing reporting and outreach for surveillance and risk-reducing surgeries for cancer genetic predisposition: Findings of a workshop organized by the International Cascade Consortium.

Public health genomics·2026
Same author

Instability in Pentanucleotide Markers in a Subset of Microsatellite Instability-High Colorectal Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

Global Proteomic Analysis of Colorectal Cancers Stratified by Microsatellite Instability Subtype Reveals Protein Differences.

bioRxiv : the preprint server for biology·2026
Same author

A scalable new model of germline cancer genomic care delivery: Assessing psychological outcomes.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Association of germline variants with KRAS-mutation status in colorectal cancer.

Scientific reports·2026

Related Experiment Video

Updated: Jun 19, 2026

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

Genetic testing for hereditary colorectal cancer.

Heather Hampel1

  • 1Division of Human Genetics, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43240, USA. Heather.Hampel@osumc.edu

Surgical Oncology Clinics of North America
|October 2, 2009
PubMed
Summary

Genetic testing for hereditary colorectal cancer syndromes is now comprehensive in North America. Advanced techniques improve detection, enabling precise risk assessment and tailored cancer surveillance for families.

More Related Videos

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
05:58

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

Related Experiment Videos

Last Updated: Jun 19, 2026

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
05:58

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

Area of Science:

  • Genetics
  • Oncology
  • Medical Diagnostics

Background:

  • Hereditary colorectal cancer syndromes significantly increase cancer risk.
  • Accurate genetic identification is crucial for effective management and surveillance.
  • Previous genetic testing methods had limitations in detecting all mutation types.

Purpose of the Study:

  • To review the current landscape of genetic testing for hereditary colorectal cancer.
  • To highlight advancements in genetic testing technologies.
  • To emphasize the clinical utility of genetic testing in managing these syndromes.

Main Methods:

  • Review of available genetic testing options for hereditary colorectal cancer genes.
  • Inclusion of techniques for detecting large genomic rearrangements.
  • Assessment of the impact of genetic testing on clinical management.

Main Results:

  • Comprehensive genetic testing is available for all known hereditary colorectal cancer genes in North America.
  • Recent improvements include enhanced detection of large rearrangements.
  • Clinicians are better equipped to identify genetic causes for affected families.

Conclusions:

  • Genetic testing is a powerful tool for diagnosing hereditary colorectal cancer syndromes.
  • Identification of the genetic cause allows for personalized cancer surveillance and risk assessment for relatives.
  • Improved testing enables better management strategies for families with hereditary colorectal cancer.